Glenmark launches fixed dose drug for diabetic patients in India

Glenmark Pharmaceuticals has reportedly made it to the front page following its declaration of setting-off as the first company in the world to introduce fixed dose combination drug in India.

The Mumbai-based drug company has established fixed dosage combination (FDC) for its copyright protected salts like Sodium Glucose Co-Transporter Inhibitor-Remogliflozin Etabonate (SGLT2i) and DPP4 (Dipeptidyl Peptidase 4 inhibitor) and other widely used medicines.

As per credible sources, the diabetic patients have been advised to take the combination with fixed ratio of Remogliflozin (100mg), Metformin (500/1000mg) and Vildagliptin (50mg) two times a day to regulate glycemic control in patients.

Glenmark has apparently launched the two drugs under the brand name Remo MV and Remozen MV. The firm enjoys the popularity of being the sole company in the world to have combined these drugs and India being the only possessor of these.

Alok Malik, Glenmark India Formulations Group VP and Business Head, quoted that diabetes has been the primary focus of the company and they have proven to be the first-line suppliers of the latest treatment options for the disease.

It has been speculated that the other drug companies have offered the same drug at the price of Rs.75, while Glenmark has launched the tablet at Rs.16.50 per unit, taking the cost of therapy to Rs.33 for two doses per day.

Apparently, DCGI gave a green flag to Glenmark for the manufacturing and marketing of the fixed combination dosage in September 2021.

On the global level, the preferred treatment to curb Type 2 diabetes amongst people has reportedly been the intake of SGLT2 and DPP4 inhibitors.

As per the claims by International Diabetes Federation, almost 7.7 crore individuals are living with diabetes as per the 2019 survey.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is reportedly an Indian origin pharma company founded in 1977 as an active pharmaceutical ingredient and drug manufacturer.